(Total Views: 470)
Posted On: 07/13/2019 2:06:28 AM
Post# of 154951
My reply to Amatuer17
The thing with mTNBC should go very fast. On one of the RP slides in people with colon cancer, metastases were "significantly reduced" after 60 days of treatment with Maraviroc.
When a company presents such information, that stock immediately flies to the sky.
Here two things CYDY can rise to the sky, first Leronlimab will not only work with mTNBC which is already quite a lot, but can then act on metastases in dozens of cancers that are CCR5 positive. The other thing is that in the next 6-7 months Leronlimab is likely to be approved for HIV-1, a drug that will reduce metastases will already be on the market. These are enormous potentials and I am waiting for Dr. RP.
The thing with mTNBC should go very fast. On one of the RP slides in people with colon cancer, metastases were "significantly reduced" after 60 days of treatment with Maraviroc.
When a company presents such information, that stock immediately flies to the sky.
Here two things CYDY can rise to the sky, first Leronlimab will not only work with mTNBC which is already quite a lot, but can then act on metastases in dozens of cancers that are CCR5 positive. The other thing is that in the next 6-7 months Leronlimab is likely to be approved for HIV-1, a drug that will reduce metastases will already be on the market. These are enormous potentials and I am waiting for Dr. RP.
(2)
(0)
